Covered Companies: Daré Bioscience
Most Recent Event
“Why Now” On-Demand Conference
August 27, 2026
On-demand video series giving investors rapid access to company leadership, recent milestones, upcoming catalysts and the opportunities management believes investors should be watching today.
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health.
NASDAQ: DARE
About
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Past Events
CEO Connect
August 25, 2026
DARÉ President & CEO, Sabrina Martucci Johnson, discusses the Company’s shift to commercial stage, upcoming revenue opportunities, Ovaprene’s positive interim Phase 3 results and what could drive value over the next 12–18 months.
Closing Bell
July 14, 2026
Closing Bell
July 14, 2026
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses tthe upcoming launch of Flora Sync LF5™ and its significance as the company’s first consumer health product and opportunity to generate direct product revenue.
What This Means
June 25, 2026
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses tthe upcoming launch of Flora Sync LF5™ and its significance as the company’s first consumer health product and opportunity to generate direct product revenue.
What This Means
March 12, 2026
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses the significance of the FDA’s IND clearance and how this milestone allows Daré to advance DARE-HPV into Phase 2 clinical development in alignment with Daré’s broader strategy to address unmet needs in women’s health.